mRNA has emerged as a potent modality for therapeutics.

• Supplied as sodium salts, pH 7.0

• Modified NTPs are commonly used for reduction of immunogenicity for in vitro transcription RNA
• No detectable RNase, DNase, phosphatase or protease contaminating activities
• ≥95% purity, as determined by HPLC
• Optimal activity and stability for up to 24 months

Incorporation of chemically modified ribonucleotides improves the efficacy of these therapies by increasing stability, reducing immunogenicity, and enhancing translatability of mRNAs.